Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Journal of the European Academy of Dermatology and Venereology2022Vol. 36(11), pp. 2087–2100
Citations Over TimeTop 10% of 2022 papers
Andreas Pinter, L. Puig, Knut Schäkel, Adam Reich, Shirin Zaheri, Antonio Costanzo, Tsen‐Fang Tsai, Saxon D. Smith, Charles Lynde, Alan Brnabic, Catherine Reed, Julie Hill, Christopher Schuster, Elisabeth Riedl, C. Paul
Abstract
These results reflect the high efficacy and early onset of skin clearance of IL-17A inhibitors observed in randomized clinical trials and confirm the effectiveness of anti-IL-17A biologics in the real-world setting.
Related Papers
- → Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study(2021)52 cited
- → Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab(2020)9 cited
- → Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study(2022)7 cited
- → Anti-interleukin-17 therapies for moderate/severe psoriasis in clinical practice: effectiveness, safety and association with clinical patient factors(2023)3 cited
- → 26718 Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients(2021)1 cited